Gastroenterologische Praxis Balsiger, Seibold & Partner

Bern CH-3012

0 studies enrolling now · 3 studies all time

What they study most

Crohn's Disease, Ulcerative Colitis

Studies at this site

• A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) — Running, not enrolling
• An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) — Completed
• A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — Completed